Publications by authors named "Jan Holubar"

Claim this Profile
P
Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.
Pierre-André Jarrot, Adrien Mirouse, Sébastien Ottaviani, Simon Cadiou, Jean-Hugues Salmon, Jan Holubar

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Easing the patients' trajectories from private practice to hospital: One-year experiment of the RAPIDO project].
Julie Bouvet, Jonathan Broner, Erik Arnaud, Cyril Dumain, Jan Holubar

Rev Med Interne· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors.
Jan Holubar, Erik Arnaud, Jonathan Broner, Yves-Marie Pers, Alain Proust

Immunol Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic performance of F-FDG-PET/CT in inflammation of unknown origin: A clinical series of 317 patients.
Jan Holubar, Jonathan Broner, Erik Arnaud, Olivier Hallé, Thibault Mura

J Intern Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.
Cyril Dumain, Jonathan Broner, Erik Arnaud, Emmanuel Dewavrin, Jan Holubar

J Clin Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak.
Jan Holubar, Moglie Le Quintrec, Hind Letaief, Jean Luc Faillie, Yves-Marie Pers

Ann Rheum Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.
Jan Holubar, Virginie Bres, Valérie Costes-Martineau, Yves-Marie Pers

Blood Cells Mol Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis